Our Principles

The company has built the global network for production, sales and R&D not only in Korea but also in main bases across the world and has provided globally competitive products including ABS, polarizers and EV battery cells, raising its global position as a material supplier. The company has strengthened market dominance starting from the Petrochemicals business to Energy Solution, Advanced Materials and has expanded its business into Life Science area, building a future-oriented business portfolio.

In the long term, the company will build the foundation for sustainable growth by selecting and concentrating on the ‘energy’, ‘water’ and ‘bio’ businesses as the new growth engines. LG Chem is committed to becoming a global company that realizes the vision of “growing with customers by providing innovative materials and solutions” and provides new values to customers.

Myungmoon Pharmaceutical have grown and evolved through research and development, production and distribution for high quality health care products,even if it is a short period ever since 1983 when taking the first step to improve national healthcare. With the founding principles, "Advancement","Harmony"and"Creation",Myungmoon Pharmaceutical have made its best efforts and then grown as one of the leading pharmaceutical companies.

Specially,Myungmoon Pharmaceutical developed transdermal drug delivery system autonomously and launched it for the first time in Korean market as the Korean pharmaceutical manufacturer. Myungmoon Pharmaceutical doing the endless efforts to realize its founding principles continues moving forward into 21st century.

Dedicated to pharmaceuticals since its foundation, Chong Kun Dang has overcome many challenges, while continuing to grow and contribute to the advancement of Korea’s pharmaceutical industry. In the days when Korea imported 100% of the raw materials required for medicines from abroad, we built Korea’s largest plants for chemical synthesis and fermentation, making it possible to produce pharmaceutical ingredients locally using our own technology. From there, we had driven Korean Pharmaceutical Industry with this breakthrough on the path toward modernization.

Furthermore, we became the first Korean pharmaceutical company to export products to the US market through the obtainment of the U.S. FDA approval. Now, on its 77th anniversary, we promise to put all efforts to lead continuous change and innovation, positioning Chong Kun Dang as a global pharmaceutical company with a competitive edge in the international market.

Serum Institute of India Pvt. Ltd. is now the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 170 countries across the globe in their national immunization programs, saving millions of lives throughout the world.

Serum Institute of India is ranked as India's No. 1 biotechnology company, manufacturing highly specialized life saving biologicals like vaccines using cutting edge genetic and cell based technologies, antisera and other medical specialties.Serum Institute of India was founded in 1966 by Dr. Cyrus Poonawalla with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by DTP (Diphtheria, Tetanus and Pertussis) group of Vaccines and then later on MMR (Measles, Mumps and Rubella) group of vaccines.

Shandong GeneLeuk Biopharmaceutical Co. Ltd of China is a Sino-US joint venture involving in the area of R&D, manufacture and marketing of recombinant DNA pharmaceuticals. The major investors are Jiufa Corporation Ltd. a listed company in Shanghai Stock Exchange, and GeneTech Biomedical Inc. a US high-tech company, who is responsible for the necessary technology and management. All the buildings and equipment were designed and constructed according to the GMP standard of FDA. GeneLeuk passed the GMP certificate of State Drug Administration of China in 1999. In the R&D, manufacturing, marketing and sales of new drugs, GeneLeuk conforms with the international standard of GLP, GCP and GMP.

R&D center of GeneLeuk is located in Long Island, New York, USA. Pilot production and manufacture bases are in JiNan City, China. Sales & marketing center is in Beijing City of China. Its product on the market is Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF or Filgrastim) with the trade mark of GeneLeukim . rhG-CSF is a haematopoietic growth factor which principally regulates the formation and development of neutrophiles within the bone marrow and stimulates their release into the peripheral circulation. GeneLeukim is indicated to decrease the incidence of infection as manifested by neutropenia in patients with malignancies receiving myelosuppression anti-cancer drugs associated with a significant incidence of severe neutropenia. For high-dose chemotherapy, GeneLeukim makes chemotherapy safer and more effective as well as reduces antibiotics use duration and hospitalization costs.